The Drug Behind Ozempic And Wegovy Pills May Also Treat Alcohol Use Disorder, New Trial Finds

A recent clinical trial from the University of Colorado Anschutz suggests that oral semaglutide, the active medication in Ozempic and Wegovy, shows promise in treating alcohol use disorder. The study examined 50 adults with moderate to severe alcohol use disorder and found that the treatment reduced heavy drinking days, decreased alcohol consumption per occasion, and lowered overall cravings.

Alcohol use disorder remains a significant health challenge in the United States, affecting millions of people. Despite its prevalence, there have been few new medication options approved for the condition since 2006. Medical experts involved in the study indicated that this medication could serve as a viable treatment path for patients who have not seen success with current clinical options.

Participants in the trial also reported reduced cannabis use, suggesting broader potential applications for the drug. The study noted that the medication was generally well-tolerated among the participants. The researchers observed high adherence to the treatment protocol throughout the trial duration.

Looking ahead, the team at CU Anschutz is planning larger and longer-term trials. These next steps are critical to confirm the initial findings and determine the most effective dosing strategies. This development represents a notable shift in how medical researchers are investigating existing diabetes and weight-loss drugs for other behavioral health conditions.